accruwebmaster

D-US-60010-001

An open-label, randomised, multicentre, phase III study of irinotecan liposome [...]

D-US-60010-001accruwebmaster2022-07-14T16:04:01+00:00

BrafPanc: A Phase II Trial of Binimetinib in combination with [...]

ACCRU-GI-1907accruwebmaster2022-03-08T01:48:16+00:00

A Phase II study of Olaparib in patients with advanced [...]

ACCRU-ICRN-1702accruwebmaster2022-03-08T01:47:39+00:00

A Phase I, Single center, Open label, Dose De-escalation and [...]

ACCRU-ICRN-1701accruwebmaster2022-03-08T01:47:52+00:00

A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor [...]

ACCRU-GI-2008accruwebmaster2022-03-08T01:48:05+00:00

INTEGRATE IIb: A Randomised Phase III Open Label Study of [...]

AG0315OG/CTC0140accruwebmaster2022-03-08T01:47:26+00:00

Ramucirumab Plus trifluridine/tipiracil (TAS-102) for Patients With Previously Treated Advanced [...]

ACCRU-GI-1810accruwebmaster2022-03-08T01:48:29+00:00

A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients [...]

ACCRU-GI-1701accruwebmaster2022-07-14T15:42:38+00:00

Blood and Stool Sample Collection in Subjects with a Diagnosis [...]

2018-07accruwebmaster2022-03-08T01:46:57+00:00

Phase II Randomized Study of Sorafenib Compared to Placebo When [...]

RC0731accruwebmaster2022-03-07T21:51:45+00:00